Results 21 to 30 of about 87,925 (315)

Genetic Polymorphisms and Adverse Events on Unbound Imatinib and Its Active Metabolite Concentration in Patients With Gastrointestinal Stromal Tumors

Frontiers in Pharmacology, 2019
Imatinib is a first-line drug for the treatment of gastrointestinal stromal tumors (GIST). This study aims to investigate the influence of different kinds of protein concentrations and genetic polymorphisms of metabolizing enzymes and drug transporters ...
Yi Qian, Lu-Ning Sun, Yang-Jie Liu, Qiang Zhang, Jiang-Hao Xu, Zeng-Qing Ma, Xue-Hui Zhang, Hao Xu, Yong-Qing Wang, Yong-Qing Wang   +9 more
doaj   +1 more source

Exploiting the promiscuity of imatinib [PDF]

Journal of Biology, 2009
The protein kinase inhibitor imatinib, also known as Gleevec, has been a notable success in treating chronic myelogenous leukemia. A recent paper in BMC Structural Biology reports a 1.75 A crystal structure of imatinib bound to the oxidoreductase NQO2 and reveals insights into the binding specificity and the off-target effects of the inhibitor.
Lee, Shun J, Wang, Jean YJ
openaire   +4 more sources

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

New England Journal of Medicine, 2006
BACKGROUND The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic ...
B. Druker, F. Guilhot, S. O’Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M. Deininger, R. Silver, J. Goldman, R. Stone, F. Cervantes, A. Hochhaus, B. Powell, J. Gabrilove, P. Rousselot, J. Reiffers, J. Cornelissen, T. Hughes, H. Agis, T. Fischer, G. Verhoef, J. Shepherd, G. Saglio, A. Gratwohl, J. L. Nielsen, J. Radich, B. Simonsson, K. Taylor, M. Baccarani, Charlene So, L. Letvak, R. Larson   +31 more
semanticscholar   +1 more source

Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

JAMA Oncology, 2020
Importance A randomized clinical trial is needed to determine whether the second-generation Abl-tyrosine kinase inhibitor dasatinib is more effective than the first-generation inhibitor imatinib mesylate for childhood Philadelphia chromosome-positive ...
S. Shen, Xiaojuan Chen, J. Cai, Jie Yu, Ju Gao, Shaoyan Hu, X. Zhai, Changda Liang, X. Ju, Hua Jiang, R. Jin, Xue-dong Wu, Ningling Wang, Xin Tian, K. Pan, Hui Jiang, Lirong Sun, Yongjun Fang, Chi-kong Li, Q. Hu, Minghua Yang, Yiping Zhu, Hui Zhang, Chunfu Li, Deqing Pei, S. Jeha, Jun J. Yang, Cheng Cheng, Jingyan Tang, Xiaofan Zhu, C. Pui   +30 more
semanticscholar   +1 more source

Imatinib

The Oncologist, 2007
Learning Objectives After completing this course, the reader will be able to: Identify the current indications for imatinib.Describe the pharmacokinetics of imatinib.Discuss the mechanisms involved in imatinib resistance. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist ...
Christine E, de Kogel, Jan H M, Schellens   +1 more
openaire   +2 more sources

Imatinib mesylate in chordoma [PDF]

Cancer, 2004
AbstractBACKGROUNDTo the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT.METHODSSix patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily ...
Casali, Paolo G., Messina, Antonella, Stacchiotti, Silvia, Tamborini, Elena, Crippa, Flavio, Gronchi, Alessandro, Orlandi, Rosaria, Ripamonti, Carla, Spreafico, Carlo, Bertieri, Raffaello, Bertulli, Rossella, Colecchia, Maurizio, Fumagalli, Elena, Greco, Angela, Grosso, Federica, Olmi, Patrizia, Pierotti, Marco A., Pilotti, Silvana   +17 more
openaire   +3 more sources

Imatinib Mesylate Reduces Voiding Frequency in Female Mice With Acute Cyclophosphamide-Induced Cystitis

Frontiers in Systems Neuroscience, 2022
Lamina propria interstitial cells that express the tyrosine kinase receptor, platelet-derived growth factor receptor alpha (PDGFRα) may play a role in urinary sensory signaling.
Megan E. Perkins, Beatrice M. Girard, Susan E. Campbell, Margaret A. Vizzard   +3 more
doaj   +1 more source

Quality-Adjusted Time Without Symptoms of Disease or Toxicity (Q-TWiST) in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Comparison of Ponatinib Versus Imatinib. [PDF]

Cancer Med
ABSTRACT Background In the phase 3 ponatinib‐3001 trial (PhALLCON, NCT03589326), ponatinib demonstrated superior efficacy over imatinib with comparable safety in patients with newly diagnosed Philadelphia‐positive acute lymphoblastic leukemia (Ph+ ALL). This post hoc analysis evaluated the net benefits of ponatinib using a quality‐adjusted time without
Ashaye A, Shi L, Aldoss I, Montesinos P, Vachhani P, Rocha V, Papayannidis C, Leonard JT, Baer MR, Ribera JM, McCloskey J, Wang J, Rane D, Guo S.   +13 more
europepmc   +2 more sources

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

New England Journal of Medicine, 2003
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have had no response to interferon alfa.
S. O’Brien, F. Guilhot, R. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J. L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A. Bolton, R. Capdeville, B. Druker   +24 more
semanticscholar   +1 more source

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.

JAMA Oncology, 2020
Importance Adjuvant imatinib is associated with improved recurrence-free survival (RFS) when administered after surgery to patients with operable gastrointestinal stromal tumor (GIST), but its influence on overall survival (OS) has remained uncertain ...
H. Joensuu, M. Eriksson, K. Sundby Hall, A. Reichardt, B. Hermes, J. Schütte, S. Cameron, P. Hohenberger, P. Jost, S. Al-Batran, L. Lindner, S. Bauer, E. Wardelmann, B. Nilsson, R. Kallio, P. Jaakkola, J. Junnila, T. Alvegård, P. Reichardt   +18 more
semanticscholar   +1 more source